Physician profile
Douglas Beach
NPI 1457598930
$4,675.68
in general payments reported to CMS, 2019-2025
15 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2021: $643 · 2023: $2,186 · 2024: $131 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,943 · Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,942.50 |
| Food and Beverage | $503.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,942.50 | 2023 | Calquence |
| Astrazeneca Uk Limited | $1,506.69 | 2019 | |
| Tg Therapeutics, INC. | $466.90 | 2021 | |
| Genmab U.S., INC. | $283.04 | 2023-2024 | Epkinly |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Abbott Laboratories | $79.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.96 | 2025 | |
| Janssen Scientific Affairs, LLC | $56.72 | 2024-2025 | Tecvayli, Talvey, Carvykti |
| Medtronic, INC. | $35.56 | 2021-2023 | Abre |
| Glaxosmithkline, LLC. | $34.65 | 2024 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $19.76 | 2025 | Keytruda, Lynparza |
| Chiesi USA, INC. | $16.20 | 2024 | Ferriprox |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Beach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.